This afternoon, CSL Ltd (ASX: CSL) announced the retirement of CEO Dr Paul McKenzie and the appointment of Gordon Naylor as interim CEO and managing director. The leadership change comes as CSL continues its strategic transformation in plasma therapies and vaccines.
Image source: Getty Images
What did CSL report?
- Dr Paul McKenzie will retire as CEO and managing director, effective 10 February 2026.
- Gordon Naylor, former CFO and President of Seqirus, appointed interim CEO & MD from 11 February.
- Naylor will not receive a short-term or long-term performance incentive but will be granted a one-off equity award valued at US$4.06 million.
- The Board highlighted CSL's recent progress, including new therapies (HEMGENIX®, ANDEMBRY®), increased plasma collections, and improved operations.
- Outgoing CEO Dr McKenzie's tenure saw expansion of R&D investment and the new Melbourne vaccine facility.
What else do investors need to know?
CSL Limited is undertaking a CEO search while Gordon Naylor steers the company as interim chief. Naylor has a deep 33-year history with CSL, having helped develop its plasma businesses and turn around its global influenza division.
The one-off restricted share units to be granted to Naylor, equal to 200% of his fixed pay, will vest after 12 months—subject to performance and holding conditions. No short-term or long-term bonuses will apply during his interim period.
Dr Paul McKenzie leaves after seven years with CSL, three of them as CEO, in which he guided the company through pandemic disruptions and operational transformations. The transition aims to ensure continuity as CSL pursues growth and new therapies.
What did CSL management say?
Incoming interim CEO & MD Gordon Naylor said:
I have had a long association with CSL. It is a great company with innovative platforms, world-class people, as well as differentiated medicines and vaccines essential for patients and communities globally. My immediate priority will be to work closely with the Board and leadership team on executing our strategic transformation and delivering for our patients, public health and shareholders.
What's next for CSL?
The company will begin a formal process to find its next permanent CEO. During this period, Naylor will focus on progressing CSL's strategy, continuing investment in research, and maintaining improvements across its global supply chain and new product introductions.
CSL's Board remains committed to driving innovation and international growth, aiming to build on foundations laid during Dr McKenzie's leadership. The transition is designed to ensure steady execution of current plans and long-term value for investors.
CSL share price snapshot
Over the past 12 months, CSL shares have declined 37%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 5% over the same period.
